BioMimics 3D螺旋中心线镍钛合金支架在慢性肢体威胁性缺血与复杂病变中的应用:MIMICS-3D注册研究三年结果
MIMICS-3D为前瞻性多中心欧洲真实世界注册研究,事后分析比较慢性肢体威胁性缺血(CLTI)与间歇性跛行、双侧钙化(PACSS 3,4)与无钙化、慢性完全闭塞(CTO)与无CTO患者,经倾向性评分匹配后36个月主要终点为临床驱动的靶病变血运重建(CD-TLR)、死亡、重大目标肢体截肢和支架通畅率。共纳入507例患者。
要点
- 36个月CLTI患者免于重大截肢率低于IC患者(92.6% vs 100%,p<.001)。
- CTO患者一期通畅率低于无CTO患者(63.9% vs 77.8%,p=.003),倾向性评分匹配后差异缩小(70.5% vs 76.8%,p=.43)。
- PACSS 3,4或CLTI患者一期通畅率未受损。
核心结论
- MIMICS-3D注册研究结果表明,BioMimics 3D支架在复杂股腘病变和CLTI的血管内治疗中有效。
- 未来随机对照试验应确认其相较于现有替代方案的非劣效性或优效性。
研究设计与样本
- MIMICS-3D为前瞻性、多中心、欧洲真实世界注册研究。
- 本分析为事后分析,比较CLTI与间歇性跛行(IC)、双侧钙化(PACSS 3,4)与无钙化(PACSS 0-2)、CTO与无CTO患者。
- 采用倾向性评分匹配以减少基线变量的影响。
- 共纳入507例患者。
主要发现
- 36个月时,CLTI患者免于重大截肢率低于IC患者(92.6% vs 100%,p<.001)。
- 一期通畅率方面,CTO患者低于无CTO患者(63.9% vs 77.8%,p=.003),倾向性评分匹配后差异缩小(70.5% vs 76.8%,p=.43)。
- PACSS 3,4患者或CLTI患者的一期通畅率未受损。
- 免于CD-TLR在各组间无显著差异:CLTI为73.8% vs IC为78.9%(p=.15);PACSS 3,4为77.6% vs PACSS 0-2为78.7%(p=.55);CTO为75.6% vs 无CTO为81.0%(p=.11)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: There is a need for improved outcomes in the endovascular treatment of patients suffering from chronic limb threatening ischaemia (CLTI), highly calcified lesions, and chronic total occlusions (CTOs). The helical centreline self expanding BioMimics 3D stent might be particularly useful in these high risk subsets, combining flexibility and fracture resistance with radial strength. Herein, the performance of the BioMimics 3D stent was assessed in these high risk subsets. METHODS: MIMICS-3D is a prospective, multicentre, European real world registry. This was a post hoc analysis, comparing patients with CLTI vs. intermittent claudication (IC), lesions with bilateral calcification vs. those without (peripheral arterial calcium scoring system [PACSS] 3,4 vs. PACSS 0 - 2), and CTO vs. no CTO. Propensity score matching was performed to reduce the impact of baseline variables. The 36 month endpoints were clinically driven target lesion revascularisation (CD-TLR), death, major target limb amputation, and stent patency. RESULTS: A total of 507 patients were enrolled. At 36 months, patients with CLTI had lower freedom from major amputation than patients with IC (92.6% vs. 100%, p < .001). In terms of primary patency, patients with CTO had lower patency rates than those without (63.9% vs. 77.8%, p = .003), but the difference reduced after propensity score matching (70.5% vs. 76.8%, p = .43). Primary patency was not impaired for patients with PACSS 3,4 or patients with CLTI. Freedom from CD-TLR was not significantly different among the groups and was 73.8% for CLTI vs. 78.9% for IC (p = .15), 77.6% for PACSS 3,4 vs. 78.7% for PACSS 0 - 2 (p = .55), and 75.6% for CTO vs. 81.0% for no CTO (p = .11). CONCLUSIONS: The outcome of the MIMICS-3D registry suggests that the BioMimics 3D stent is effective in the endovascular treatment of complex femoropopliteal lesions and in CLTI. Future randomised controlled trials should confirm its non-inferiority or superiority compared with existing alternatives.
引用
- Rammos C, Zeller T, Piorkowski M, et al. The BioMimics 3D Helical Centreline Nitinol Stent in Chronic Limb Threatening Ischaemia and Complex Lesions: Three Year Outcomes of the MIMICS-3D Registry. Eur J Vasc Endovasc Surg. 2024. PMID: 38447693. doi:10.1016/j.ejvs.2024.02.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。